Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hypolipidemic effect of gevilon]

I A Shevchenko, N P Alisova, T D Astashkina

    Kardiologiia
    |January 1, 1993
    PubMed
    Summary

    Gevilon demonstrates significant hypolipidemic effects, effectively lowering cholesterol and triglycerides in patients with coronary heart disease and hypertension. This drug shows promise for managing lipid disorders and improving cardiovascular health.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Soft spherical nanostructures with a dodecagonal quasicrystal-like order.

    Soft matter·2015
    Same author

    [Pharmacogenetics of community-acquired pneumonia].

    Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic]·2011
    Same author

    [Antibiotic therapy of mild community-acquired pneumonia in inpatients].

    Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic]·2010
    Same author

    [Antibiotic therapy of severe community-acquired pneumonia].

    Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic]·2009
    Same author

    [Hypertension in obese patients: the role of leptin].

    Kardiologiia·2002
    Same author

    [Phosphocreatine in the treatment of patients with myocardial infarct: effects on hemodynamics and oxygen supply].

    Kardiologiia·1990

    Area of Science:

    • Cardiovascular Pharmacology
    • Lipid Metabolism
    • Clinical Therapeutics

    Context:

    • Investigates the therapeutic potential of Gevilon, a novel hypolipidemic agent.
    • Focuses on patients with coronary heart disease and severe lipid metabolic disturbances.
    • Addresses the clinical need for effective lipid-lowering therapies.

    Purpose:

    • To evaluate the hypolipidemic efficacy and tolerability of Gevilon.
    • To assess Gevilon's impact on lipid profiles, including total cholesterol, beta-cholesterol, triglycerides, and alpha-cholesterol.
    • To determine the optimal application of Gevilon in managing dyslipoproteinemia.

    Summary:

    • Gevilon treatment in 53 patients with coronary heart disease and hypertension resulted in significant reductions in total cholesterol, beta-cholesterol, and triglycerides.
    • The drug effectively increased alpha-cholesterol levels and normalized the atherogenicity coefficient, indicating improved lipid profiles.
    • Gevilon exhibited its most pronounced hypolipidemic effects in patients with Type IIb dyslipoproteinemia.
    • The drug was well-tolerated and suitable for combination therapy with existing treatments for coronary heart disease and hypertension.

    Impact:

    • Gevilon represents a promising therapeutic option for managing hyperlipidemia in patients with cardiovascular conditions.
    • Clinical findings support Gevilon's role in improving lipid profiles and potentially reducing cardiovascular risk.
    • The drug's favorable tolerability profile enhances its clinical utility in complex therapeutic regimens.

    Related Experiment Videos